A Rush to Judgment? Rapid Reporting and Dissemination of Results and Its Consequences Regarding the Use of Hydroxychloroquine for COVID-19.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 32227189.
- Also identified by DOI 10.7326/M20-1223 and PMC identifier 7138335.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Hydroxychloroquine, an essential treatment for many patients with rheumatologic conditions, has recently garnered widespread attention as a potential treatment for COVID-19 infection. The authors appraise the study generating this interest and highlight the potential consequences of rapid dissemination of overinterpreted data, particularly for people with conditions for which hydroxychloroquine has demonstrated benefits in preventing organ damage and life-threatening disease flares.
Medical subject headings
- Antiviral Agents
- Clinical Trials as Topic
- Coronavirus Infections
- Hydroxychloroquine
- Information Dissemination
- Mass Media
- Pandemics
- Pneumonia, Viral